http://www.viralytics.com/wp-conten...date-Report-ROTH-Capital-14-November-2016.pdf
We are impressed by the first CAPRA look and believe both it and the recent MITCI update (CAVATAK + Yervoy) continue to strengthen the company's position.
A major takeaway, in our belief, is that the data represent an impressive translation from preclinical models to the clinical setting. While patient numbers are small, the response rates point to synergy of the two agents and the combination was safe and well tolerated. Reiterate Buy / A $4.50 target.
- Forums
- ASX - By Stock
- VLA
- Roth sitting on $4.50
Roth sitting on $4.50
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)